BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BBCI Announces Its New Partnership With VIGIUN, A CRO Headquartered In Sao Paulo, Brazil


10/19/2005 5:11:21 PM

KANSAS CITY, Mo., and SAO PAULO, Brazil, July 28 /PRNewswire/ -- BBCI, a leading provider of innovative Phase II-IV clinical trials solutions and post-marketing studies, has announced a new partnership with VIGIUN, a Brazilian CRO, headquartered in Sao Paulo, Brazil which specializes in clinical and epidemiological research.

This partnership means that BBCI, which operates a European partnership with Advanced Medical Services (AMS) headquartered in Mannheim, Germany, has nearly 300 associates conducting clinical trials in North America, Eastern and Western Europe and Latin America. BBCI is the only CRO in the world focusing their expertise in late-stage drug development.

Sean Hart, BBCI's CEO, stated, "Over the past year, BBCI and VIGIUN have formed a strong bond with quality and top level service at its foundation. With this partnership and a continued focus on late-stage drug development, BBCI is able to offer our clients a growing international presence. This partnership will open up new streams of investigators, patients and markets in Latin America to complement our current offerings in North America and Europe, in order to assist the development of our clients' products."

Eduardo Forleo, VIGIUN's Medical Director stated, "Our purpose is to assist pharmaceutical companies to conduct their research programs, and thus to ensure greater quality and excellence in all projects within adequate timelines. With this new partnership between BBCI, AMS and VIGIUN, it is doubtless that we can achieve international success by the use of each partners' regional expertise."

Brazil and Latin America form the seventh largest pharmaceutical market in the world. Brazil is at the core of the pharmaceutical industry in Central and South America with 370 pharmaceutical companies, 26 of which are responsible for 85% of clinical trials. Large concentrations of possible patients in major cities, large numbers of potential investigators, many with clinical experience, and low production costs all create an environment ripe for development through this partnership.

About BBCI:

BBCI is a high-quality, cost-effective Contract Research Organization dedicated to delivering on-time, reliable clinical trial management services to clients around the world. BBCI has been providing quality results in Phase II-IV studies for more than 28 years and has extensive post-marketing surveillance experience in every major therapeutic area, with more than 100,000 patients enrolled in studies during the past five years. More information about BBCI can be found at http://www.bbclinical.com/ , or by calling 1-800-366-8531.

About VIGIUN:

VIGIUN is a quality Contract Research Organization located in Sao Paulo in southeast Brazil. VIGIUN provides therapeutic experience in epidemiological studies including respiratory disease and gastroenterology. They are well experienced in Large Phase IV studies, clinical research and data management. More information about VIGIUN can be found at http://www.vigiun.com.br/ or by calling (55 11) 3842-2277.

BBCI

CONTACT: Chris Blandin of BBCI, +1-816-421-6400,chris.b@bbclinical.com



Read at BioSpace.com

BBCI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES